169 related articles for article (PubMed ID: 32384260)
1. c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs.
Lee ME; Tepede AA; Mandl A; Weinstein LS; Del Rivero J; Agarwal SK; Blau JE
J Mol Endocrinol; 2020 Aug; 65(2):R1-R17. PubMed ID: 32384260
[TBL] [Abstract][Full Text] [Related]
2. A novel germline mutation at exon 10 of MEN1 gene: a clinical survey and positive genotype-phenotype analysis of a MEN1 Italian family, including monozygotic twins.
Palermo A; Capoluongo E; Del Toro R; Manfrini S; Pozzilli P; Maggi D; Defeudis G; Pantano F; Coppola R; Di Matteo FM; Raffaelli M; Concolino P; Falchetti A
Hormones (Athens); 2018 Sep; 17(3):427-435. PubMed ID: 30083881
[TBL] [Abstract][Full Text] [Related]
3. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
4. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.
Vicentini C; Fassan M; D'Angelo E; Corbo V; Silvestris N; Nuovo GJ; Scarpa A
Molecules; 2014 Feb; 19(2):2458-68. PubMed ID: 24566314
[TBL] [Abstract][Full Text] [Related]
5. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis.
Pieterman CR; Conemans EB; Dreijerink KM; de Laat JM; Timmers HT; Vriens MR; Valk GD
Endocr Relat Cancer; 2014 Jun; 21(3):R121-42. PubMed ID: 24389729
[TBL] [Abstract][Full Text] [Related]
6. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
7. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
8. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?
Luo Y; Chen J; Shen B; Wang M; Cai H; Xu L; Chen L; Chen M; Li ZP; Feng ST
Eur Radiol; 2018 Dec; 28(12):5250-5257. PubMed ID: 29876704
[TBL] [Abstract][Full Text] [Related]
9. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
[TBL] [Abstract][Full Text] [Related]
10. FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.
Briest F; Berg E; Grass I; Freitag H; Kaemmerer D; Lewens F; Christen F; Arsenic R; Altendorf-Hofmann A; Kunze A; Sänger J; Knösel T; Siegmund B; Hummel M; Grabowski P
Oncotarget; 2015 Apr; 6(10):8185-99. PubMed ID: 25797272
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
Strosberg JR
Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
Ryan P; Phan AT; Adelman DT; Iwasaki M
Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
[TBL] [Abstract][Full Text] [Related]
13. Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression.
Pereira SS; Pereira R; Santos AP; Costa MM; Morais T; Sampaio P; Machado B; Afonso LP; Henrique R; Monteiro MP
Pathology; 2019 Oct; 51(6):593-599. PubMed ID: 31466863
[TBL] [Abstract][Full Text] [Related]
14. Glutaminases in slowly proliferating gastroenteropancreatic neuroendocrine neoplasms/tumors (GEP-NETs): Selective overexpression of mRNA coding for the KGA isoform.
Szeliga M; Ćwikła J; Obara-Michlewska M; Cichocki A; Albrecht J
Exp Mol Pathol; 2016 Feb; 100(1):74-8. PubMed ID: 26581715
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.
Buil-Bruna N; Garrido MJ; Dehez M; Manon A; Nguyen TX; Gomez-Panzani EL; Trocóniz IF
Clin Pharmacokinet; 2016 Apr; 55(4):461-73. PubMed ID: 26416534
[TBL] [Abstract][Full Text] [Related]
16. Biotherapies for GEP-NETs.
Öberg K
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):833-41. PubMed ID: 23582922
[TBL] [Abstract][Full Text] [Related]
17. Natural History of MEN1 GEP-NET: Single-Center Experience After a Long Follow-Up.
Giudici F; Cavalli T; Giusti F; Gronchi G; Batignani G; Tonelli F; Brandi ML
World J Surg; 2017 Sep; 41(9):2312-2323. PubMed ID: 28429092
[TBL] [Abstract][Full Text] [Related]
18. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
20. Clinically Defined Mutations in
Duan S; Sheriff S; Elvis-Offiah UB; Witten BL; Sawyer TW; Sundaresan S; Cierpicki T; Grembecka J; Merchant JL
Cancer Res Commun; 2023 Jul; 3(7):1318-1334. PubMed ID: 37492626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
